Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 8/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950990 | 0.83 | GCGR (0.61) | GCGHCAR3GCGR | |
| SCHEMBL9951401 | 0.79 | GCGR (0.54) | GCGHCAR3GCGR | |
| SCHEMBL9951398 | 0.79 | GCGR (0.54) | GCGHCAR3GCGR | |
| SCHEMBL9951339 | 0.77 | GCGR (0.71) | GCGHCAR3GCGR | |
| SCHEMBL9951763 | 0.75 | GCGR (0.55) | GCGGCGR | |
| SCHEMBL11962743 | 0.75 | GCG (0.60) | GCGGCGR | |
| SCHEMBL718064 | 0.73 | GABRA5 (0.40) | GCGHCAR3GCGRMAPK1 | |
| SCHEMBL11962640 | 0.72 | GCG (0.74) | GCGGCGR | |
| SCHEMBL16423444 | 0.72 | HCAR3 (0.40) | GCGHCAR3GCGRMAPK1KDM4E | |
| SCHEMBL9951730 | 0.71 | GCGR (0.65) | GCGHCAR3GCGRHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8933104-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329862-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329862-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885HCAR3 180/4885GCGR 2/4885 |
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885HCAR3 180/4885GCGR 2/4885 |
| US-20120165343-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885HCAR3 180/4885GCGR 2/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCG 15/4885HCAR3 180/4885GCGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.